Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Lowers Expected Proceeds from IPO, Increases 2012 Revenues

NEW YORK (GenomeWeb News) – Cancer Genetics again lowered the amount it expects to raise in its pending initial public offering.

In a Form S-1/A filed with the US Securities and Exchange Commission on Monday, the Rutherford, NJ-based firm said that it expects to offer 1.85 million shares of stock in its IPO at a price of between $10 and $12 per share.

At the midpoint price of $11 per share, net proceeds from the offering is estimated at $16.3 million, Cancer Genetics said. If the offering's underwriters, Aegis Capital and Feltl and Co., exercise their over-allotment option, the net proceeds would rise to about $19.2 million, it added.

Cancer Genetics filed for its IPO in late December 2011, hoping to raise $48.6 million, but it has lowered that target several times, most recently to $23.5 million.

The company effected a one-for-two reverse stock split on February 8, and a one-for-2.5 reverse stock split on March 1.

If approved, Cancer Genetics' stock would list on Nasdaq under ticker symbol "CGIX".

Proceeds from the IPO would be used to repay "certain outstanding indebtedness"; fund R&D and regulatory submissions, as well as potential product launches and collaboration; hire additional sales and marketing staff; fund Cancer Genetics' joint venture with the Mayo Foundation for Medical Education and Research to develop oncology diagnostic services and tests using next-generation sequencing; and fund ongoing operations and business expansion, the company said.

The company also disclosed its earnings for 2012 in its SEC document. For full-year 2012 it took in $4.3 million in revenues, up 43 percent from $3.0 million in 2011.

Its R&D expenses were essentially flat at $2.1 million, while its SG&A costs were down 2 percent to $5.9 million from $6.0 million.

Cancer Genetics' net loss for the year was $6.7 million, or $10.55 per share, compared to a net loss of $19.9 million, or $15.61 per share, in 2011.

Last week, the firm announced it received CLIA and New York State approval for the clinical use of its mature B-cell neoplasm array to assist clinicians in the diagnosis and prognosis of diffuse large B-cell lymphoma.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.